🏢 官网IRVSTMCodex · 实盘不做把握 9/10
北京时间·🕒 发布 19:30:00时区推断·⟳ 抓取 19:36:31·⚡ 决策 07-23 19:38:03 +1m32s·96.0 天前
Verastem Oncology宣布将于2026年8月6日披露二季度财报
这只是公司官方披露财报发布时间和网络会议安排，没有新增经营、临床、监管或财务数据。
📄 原文VSTM↗ 原文
Verastem Oncology to Report Second Quarter 2026 Financial Results on August 6, 2026
Press Release << Back Verastem Oncology to Report Second Quarter 2026 Financial Results on August 6, 2026 A live audio…
不做 Verastem Oncology（VSTM.US）
例行财报日程通知，没有业绩数据、指引变化、临床或监管新增信息，方向不明且无可交易edge。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
🔎 新鲜度:最早出现 2026-07-23 · 扩散 low · price-in 风险 low ↗
关键理由
- 这只是公司官方披露财报发布时间和网络会议安排，没有新增经营、临床、监管或财务数据。
主要风险
- 真正可交易信息需等2026年8月6日财报或电话会披露后再重新研判。
原文全文
展开原文 · 1,181 字
Press Release
<< Back
Verastem Oncology to Report Second Quarter 2026 Financial Results on August 6, 2026
A live audio webcast of the call, along with accompanying slides, will be available under "Events & Presentations" in the Investor section of the Company's website, https://investor.verastem.com/events. A replay of the webcast will be archived and available following the event.
About Verastem Oncology
Verastem Oncology (Nasdaq: VSTM) is a biopharmaceutical company committed to developing and commercializing new medicines to improve the lives of patients diagnosed with RAS/MAPK pathway-driven cancers. Verastem markets AVMAPKI® FAKZYNJA® CO-PACK in the U.S. Our pipeline is focused on novel small molecule drugs that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, including RAF/MEK inhibition, FAK inhibition, and KRAS G12D inhibition. For more information, please visit www.verastem.com and follow us on LinkedIn.
For Investor and Media Inquiries:
Julissa Viana
Senior Vice President, Corporate Communications,
Investor Relations & Patient Advocacy
investors@verastem.com or
media@verastem.com
Source: Verastem Oncology
<< Back
Verastem Oncology to Report Second Quarter 2026 Financial Results on August 6, 2026
A live audio webcast of the call, along with accompanying slides, will be available under "Events & Presentations" in the Investor section of the Company's website, https://investor.verastem.com/events. A replay of the webcast will be archived and available following the event.
About Verastem Oncology
Verastem Oncology (Nasdaq: VSTM) is a biopharmaceutical company committed to developing and commercializing new medicines to improve the lives of patients diagnosed with RAS/MAPK pathway-driven cancers. Verastem markets AVMAPKI® FAKZYNJA® CO-PACK in the U.S. Our pipeline is focused on novel small molecule drugs that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, including RAF/MEK inhibition, FAK inhibition, and KRAS G12D inhibition. For more information, please visit www.verastem.com and follow us on LinkedIn.
For Investor and Media Inquiries:
Julissa Viana
Senior Vice President, Corporate Communications,
Investor Relations & Patient Advocacy
investors@verastem.com or
media@verastem.com
Source: Verastem Oncology
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。